BR112017003252A2 - terapia com anticorpos contra hiv como substituto de tratamento - Google Patents
terapia com anticorpos contra hiv como substituto de tratamentoInfo
- Publication number
- BR112017003252A2 BR112017003252A2 BR112017003252A BR112017003252A BR112017003252A2 BR 112017003252 A2 BR112017003252 A2 BR 112017003252A2 BR 112017003252 A BR112017003252 A BR 112017003252A BR 112017003252 A BR112017003252 A BR 112017003252A BR 112017003252 A2 BR112017003252 A2 BR 112017003252A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- antibody therapy
- hiv antibody
- substitute
- treatment substitute
- Prior art date
Links
- 238000009175 antibody therapy Methods 0.000 title abstract 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 2
- 238000002625 monoclonal antibody therapy Methods 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção refere-se ao uso de terapias com anticorpos como um substituto de tratamento ou para interrupção do tratamento, para o tratamento de pacientes infectados pelo hiv-1. especificamente, a presente invenção se refere ao uso de terapias com anticorpos, como terapia com anticorpos monoclonais pro 140 como monoterapia para tratamento de pacientes infectados pelo hiv-1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462039620P | 2014-08-20 | 2014-08-20 | |
| US201562192941P | 2015-07-15 | 2015-07-15 | |
| PCT/US2015/046160 WO2016029049A1 (en) | 2014-08-20 | 2015-08-20 | Hiv antibody therapy as treatment substitute |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017003252A2 true BR112017003252A2 (pt) | 2017-11-28 |
Family
ID=55351264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017003252A BR112017003252A2 (pt) | 2014-08-20 | 2015-08-20 | terapia com anticorpos contra hiv como substituto de tratamento |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10562969B2 (pt) |
| EP (2) | EP3904390A1 (pt) |
| JP (2) | JP6767367B2 (pt) |
| KR (1) | KR20170042706A (pt) |
| CN (1) | CN106661113A (pt) |
| AU (2) | AU2015305401A1 (pt) |
| BR (1) | BR112017003252A2 (pt) |
| CA (1) | CA2957817A1 (pt) |
| ES (1) | ES2880950T3 (pt) |
| MX (1) | MX2017002093A (pt) |
| WO (1) | WO2016029049A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11584797B2 (en) | 2015-06-23 | 2023-02-21 | Cytodyn Inc. | Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions |
| EP3684815A1 (en) * | 2017-09-18 | 2020-07-29 | CytoDyn Inc. | Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy |
| WO2024008177A1 (en) * | 2022-07-08 | 2024-01-11 | Nanjing Curegene Technology Co., Ltd. | Engineered cells and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| AU2004251228B2 (en) * | 2003-05-16 | 2008-04-24 | University Of Maryland Biotechnology Institute | Compositions for down-regulation of CCR5 expression and methods of use therefor |
| CN101495145A (zh) * | 2005-07-22 | 2009-07-29 | 原基因药物有限公司 | 用于减少受hiv-1感染的患者中病毒负荷的方法 |
| EP2150817A4 (en) | 2007-04-30 | 2011-09-07 | Progenics Pharm Inc | PROCEDURE FOR REDUCING VIRUS LOAD IN HIV-1 INFECTED PATIENTS |
| US10500274B2 (en) | 2008-04-30 | 2019-12-10 | Cytodyn Inc. | Methods for reducing viral load in HIV-1 infected patients |
| NZ602685A (en) | 2010-03-01 | 2014-10-31 | Cytodyn Inc | Concentrated protein formulations and uses thereof |
-
2015
- 2015-08-20 AU AU2015305401A patent/AU2015305401A1/en not_active Abandoned
- 2015-08-20 US US15/504,928 patent/US10562969B2/en not_active Expired - Fee Related
- 2015-08-20 EP EP21166771.2A patent/EP3904390A1/en not_active Withdrawn
- 2015-08-20 EP EP15832985.4A patent/EP3183270B1/en active Active
- 2015-08-20 CN CN201580044550.6A patent/CN106661113A/zh active Pending
- 2015-08-20 WO PCT/US2015/046160 patent/WO2016029049A1/en active Application Filing
- 2015-08-20 ES ES15832985T patent/ES2880950T3/es active Active
- 2015-08-20 JP JP2017529600A patent/JP6767367B2/ja active Active
- 2015-08-20 MX MX2017002093A patent/MX2017002093A/es unknown
- 2015-08-20 BR BR112017003252A patent/BR112017003252A2/pt not_active Application Discontinuation
- 2015-08-20 CA CA2957817A patent/CA2957817A1/en not_active Abandoned
- 2015-08-20 KR KR1020177007086A patent/KR20170042706A/ko not_active Application Discontinuation
-
2020
- 2020-01-08 US US16/737,291 patent/US20200385475A1/en not_active Abandoned
- 2020-09-17 JP JP2020155978A patent/JP7035143B2/ja active Active
-
2021
- 2021-04-07 AU AU2021202132A patent/AU2021202132A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN106661113A (zh) | 2017-05-10 |
| US20200385475A1 (en) | 2020-12-10 |
| EP3183270B1 (en) | 2021-04-28 |
| MX2017002093A (es) | 2017-05-25 |
| US10562969B2 (en) | 2020-02-18 |
| WO2016029049A1 (en) | 2016-02-25 |
| US20170335002A1 (en) | 2017-11-23 |
| AU2021202132A1 (en) | 2021-05-06 |
| ES2880950T3 (es) | 2021-11-26 |
| JP2017527613A (ja) | 2017-09-21 |
| JP2021004249A (ja) | 2021-01-14 |
| EP3183270A4 (en) | 2018-01-17 |
| JP7035143B2 (ja) | 2022-03-14 |
| EP3183270A1 (en) | 2017-06-28 |
| EP3904390A1 (en) | 2021-11-03 |
| JP6767367B2 (ja) | 2020-10-14 |
| AU2015305401A1 (en) | 2017-03-02 |
| CA2957817A1 (en) | 2016-02-25 |
| KR20170042706A (ko) | 2017-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124756T1 (el) | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας | |
| GT201700033A (es) | Anticuerpos anti tigit | |
| EA201890735A1 (ru) | Модуляторы корового белка вируса гепатита b | |
| MX2022005253A (es) | Anticuerpos neutralizantes de poliomavirus. | |
| BR112017000664A2 (pt) | anticorpo anti-pd-1 e seu uso | |
| EA201790024A1 (ru) | Модуляторы toll-подобных рецепторов для лечения вич | |
| EA032929B1 (ru) | Нейтрализующее вирус иммунодефицита человека антитело и способы его применения | |
| IN2013MU01749A (pt) | ||
| BR112019002734A2 (pt) | tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart | |
| BR112016023554A2 (pt) | novos compostos macrocíclicos | |
| BR112016020260A8 (pt) | uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática | |
| TWD180966S (zh) | 安全注射器 | |
| IN2014MN01907A (pt) | ||
| CL2017000212A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| BR112017003252A2 (pt) | terapia com anticorpos contra hiv como substituto de tratamento | |
| BR112018013256A2 (pt) | anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo | |
| BR112017016333A2 (pt) | compostos anticâncer | |
| EA201692471A1 (ru) | Антиретровирусное лекарственное средство, нацеленное на эндогенный ретровирус человека | |
| CL2015000362A1 (es) | Compuestos derivados de tris-(hetero)aril-pirazoles; procedimiento de preparacion; medicamento; y su uso para el tratamiento y/o profilaxis de infecciones con retrovirus, en especial vih | |
| EA201501130A1 (ru) | Офтальмологическая фармацевтическая композиция | |
| BR112016030291A2 (pt) | terapia de combinação | |
| EA201990041A1 (ru) | Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| AR120118A2 (es) | Anticuerpos anti tigit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |